TY  - GEN
AU  - Kleeberg,U R
AU  - Suciu,S
AU  - Bröcker,E B
AU  - Ruiter,D J
AU  - Chartier,C
AU  - Liénard,D
AU  - Marsden,J
AU  - Schadendorf,D
AU  - Eggermont,A M M
TI  - Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
SN  - 0959-8049
PY  - 2004///0227
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Disease-Free Survival
KW  - Feasibility Studies
KW  - Female
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Interferon-gamma
KW  - Lymphatic Metastasis
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Plant Extracts
KW  - Plant Proteins
KW  - Recombinant Proteins
KW  - Risk Factors
KW  - Skin Neoplasms
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1016/j.ejca.2003.07.004
ER  -